Ellence Research Fund Names 11 Grant Recipients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 3
Volume 10
Issue 3

PEAPACK, NJ- Pharmacia Oncology has announced the 11 recipients of its first $1 million Ellence Research Fund, aimed at promoting research to advance the use of anthracyclines in various cancer settings. The recipients were chosen by a scientific advisory board composed of leading oncologists. The company has created a second $1 million Ellence Research Fund and is currently accepting research proposals.

PEAPACK, NJ— Pharmacia Oncology has announced the 11 recipients of its first $1 million Ellence Research Fund, aimed at promoting research to advance the use of anthracyclines in various cancer settings. The recipients were chosen by a scientific advisory board composed of leading oncologists. The company has created a second $1 million Ellence Research Fund and is currently accepting research proposals. (For more information, contact Lynn Stoltzfus at lynn.stoltzfus@am.pnu.com.)

The 2001 winners are: Glenn Bubley, MD, Beth Israel Deaconess Medical Center, Boston; Joan Bull, MD, University of Texas-Houston Medical School; Luke Dreisbach, MD, Arizona Cancer Center, Tucson; Phil Gold, MD, Swedish Medical Center Tumor Institute, Seattle; Daniel Haller, MD, University of Pennsylvania Cancer Center, Philadelphia; and Jon Herrington, PhD, Scott and White Memorial Hospital, Temple, Texas.

Also, Peter Kennedy, MD, Kenmar Research Institute, Los Angeles; Pam Khosla, MD, Rush-Presbyterian-St. Luke’s Medical Center, Chicago; Silvana Martino, DO, John Wayne Cancer Institute, Santa Monica, California; Lajos Pusztai, PhD, M.D. Anderson; and Christopher Ryan, MD, University of Chicago.

Recent Videos
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Earlier and more frequent talks about disabling ICDs with patients receiving end-of-life care and their families may help avoid excessive pain.
3 experts in this video
3 experts in this video
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
6 experts are featured in this series.
Related Content